February 5, 2025 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "poten ...

Revenue Performance - Revenue for the first quarter of fiscal 2025 was $81.5 billion, representing a 12.8 percent increase year-over-year, driven by a 13.6 percent increase in the U.S. Healthcare Solutions segment[1][5] - U.S. Healthcare Solutions revenue was $74.0 billion, an increase of 13.6 percent year-over-year, with segment operating income rising 9.9 percent to $767.3 million[8][10] - International Healthcare Solutions revenue was $7.5 billion, a 5.5 percent increase year-over-year, with operating income decreasing by 2.9 percent[10] - Total revenue for the same period increased by 12.8% year-over-year, reaching $81.49 billion, driven by a 13.6% increase in U.S. Healthcare Solutions revenue[32] - For Q1 fiscal 2025, the company's revenue was $81.5 billion, negatively impacted by foreign currency translation of $216.8 million, resulting in constant currency revenue of $81.7 billion[42] - The International Healthcare Solutions segment reported revenue of $7.5 billion, with a constant currency revenue of $7.7 billion after accounting for foreign currency translation[42] Earnings and Income - Adjusted diluted EPS guidance for fiscal 2025 has been raised to a range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45[2][16] - Operating income for the first quarter was $706 million, a 14.2 percent decrease compared to the same period last year, primarily due to increased operating expenses[4][5] - Adjusted operating income for the first quarter was $949 million, a 7.2 percent increase compared to the prior year[9] - Net income attributable to Cencora, Inc. was $488,600, a decrease of 18.8% from $601,500 in the prior year, resulting in diluted earnings per share of $2.50, down 16.1%[25] - Adjusted Non-GAAP net income was $727,796, reflecting a 13.7% increase compared to the prior year, with adjusted diluted earnings per share of $3.73[27] - GAAP net income for the three months ended December 31, 2023, was $601.5 million, with diluted earnings per share of $2.98[30] Expenses and Costs - Total operating expenses increased by 12.5% to $1,851,784, with distribution, selling, and administrative expenses rising by 5.2% to $1,472,055[25] - The company incurred a $35.5 million loss on the divestiture of non-core businesses during the quarter[27] - Interest expense decreased by 31.1% to $27,933, down from $40,564 in the previous year[25] - Net interest expense decreased by 31.1 percent to $27.9 million, attributed to higher interest income from increased cash balances[5][9] Dividends and Shareholder Returns - The company declared a quarterly cash dividend of $0.55 per common share, payable on March 3, 2025[17] Acquisitions and Strategic Moves - The acquisition of Retina Consultants of America was completed on January 2, 2025, enhancing the company's leadership in Specialty healthcare services[3][11] - The company plans to finance a portion of the upcoming acquisition of Retina Consultants of America with $1.8 billion in senior notes[37] Tax and Financial Metrics - The effective tax rate for the first quarter was 20.4 percent, down from 23.0 percent in the prior year[5] - The adjusted effective tax rate is calculated by dividing adjusted income tax expense by adjusted income before income taxes, providing a clearer view of the company's tax performance excluding unusual items[44] Cash Flow and Liquidity - Cash and cash equivalents at the end of the period totaled $3.22 billion, an increase from $3.13 billion at the end of the previous quarter[35] - The company experienced a net cash used in operating activities of $2.72 billion, compared to $885.16 million provided in the same period last year[37] - Long-term debt increased to $5.94 billion, up from $3.81 billion in the previous quarter[35] Non-GAAP Measures and Adjustments - Adjusted diluted earnings per share excludes impacts from antitrust litigation settlements, LIFO expense, and other non-recurring items, reflecting ongoing operational performance[44] - Adjusted net income attributable to the company excludes unusual, non-operating, unpredictable, non-recurring, or non-cash items, providing a clearer picture of ongoing performance[44] - Adjusted gross profit margin is calculated as adjusted gross profit divided by total revenue, providing insight into the company's core operating performance[41] - The company emphasizes the importance of non-GAAP financial measures to evaluate operating performance and financial planning[41]

The upcoming report from Cencora (COR) is expected to reveal quarterly earnings of $3.50 per share, indicating an increase of 6.7% compared to the year-ago period. Analysts forecast revenues of $78.12 billion, representing an increase of 8.1% year over year.Over the last 30 days, there has been an upward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of t ...

Cencora (COR) is slated to report first-quarter fiscal 2025 results on Feb. 05, before market open.In the last reported quarter, the company delivered an earnings surprise of 4.05%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.97%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $78.12 billion, up 8.1% from the prior-year quarter’s level. The consensus mark f ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.Shares of this Zacks Rank #2 (Buy) company have risen 10.8% in the past six months against the industry’s 11% decline. The S&P 500 Index has increased 12.3% in the same time frame.Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs ...

Nationally ranked stock picker for 30 years. Victory Formation and Bottom Fishing Club quant-sort pioneer.....Paul Franke is a private investor and speculator with 38 years of trading experience. Mr. Franke was Editor and Publisher of the Maverick Investor® newsletter during the 1990s, widely quoted by CNBC®, Barron’s®, the Washington Post® and Investor’s Business Daily®. Paul was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest® during ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |------------------------------|-----------------------------|----------------------|-------------------------------| | | | | | | FOR THE TRANSITION | PERIOD | FRO ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy.The strategy helps investors gain exposure to undervalued stocks with impressive prospects. Unlike a blend strategy, a portfolio that uses GARP investing is expected to include stocks that offer the best value and growth investing. Cencora, Inc. (COR) , Raymond James Financial (RJF) and Cintas Corporation (CTAS) are some GARP stocks that hold promise. ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 19.7% against 8.9% decline of the industry. The S&P 500 composite has risen 24.5% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical service companies. It focuses on providing drug distribut ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cencora (COR) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cencora is a member of our Medical group, which includes 1023 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individua ...